BenevolentAI
![Merck KGaA AI drug discovery, BenevolentAI Exscientia collaboration, AI platforms for small molecules, Merck KGaA oncology immunology targets, BenevolentAI Exscientia milestones and royalties, AI-enabled drug discovery challenges, Merck KGaA stock price MRK,](https://pharmtales.com/wp-content/uploads/2023/09/Merck-KGaA-signs-two-deals-with-BenevolentAI-and-Exscientia-to-boost-AI-driven-drug-discovery-in-oncology-and-immunology.jpg)
Merck KGaA signs two deals with BenevolentAI and Exscientia to boost AI-driven drug discovery in oncology and immunology
Anika Sharma
Merck KGaA is making strategic moves in the field of AI-enabled drug discovery by entering into three-target partnerships with BenevolentAI ...